TYRA · Tyra Biosciences, Inc.
$31.06
-0.58% last session
End-of-day data · updated 2026-07-29
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-10.8
Dividend yield
—
Beta
0.76
Avg volume
1M
Employees
0K
2D change
-0.58%
5D change
0.82%
10D change
-3.89%
30D change
-3.83%
60D change
-7.57%
MTD change
5.00%
YTD change
17.46%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — TYRA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-17
Latest call per bank · past 12 months
Bank of America
Buy$42.00
+35.2% vs priceJefferies
Buy$43.00
+38.4% vs priceBarclays
Overweight$59.00
+90.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-17 | Jones Trading | Initiates | Buy | $0.00 → $56.00 |
| 2026-06-10 | Bank of America | Maintains | Buy | $37.00 → $42.00 |
| 2026-05-19 | Wolfe Research | Initiates | Peer Perform | $0.00 |
| 2026-05-14 | HC Wainwright & Co. | Reiterates | Buy | $45.00 |
| 2026-04-15 | Guggenheim | Initiates | Buy | $0.00 → $54.00 |
| 2026-04-06 | Canaccord Genuity | Initiates | Buy | $0.00 → $50.00 |
| 2026-03-20 | Piper Sandler | Maintains | Overweight | $42.00 → $56.00 |
| 2026-02-24 | Cantor Fitzgerald | Initiates | Overweight | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 48 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.2% above the 50-day MA ($30.83).
- Price vs 200-day MA: Trading 8.0% above the 200-day MA ($28.60).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.17) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($10.10) and high ($39.61).
TYRA Price Chart
Loading chart for TYRA…
Fundamentals
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$124B 8.2% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$73B -9.7% YTD
ARGX
argenx SE
$55B 3.7% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$39B -27.5% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.8% YTD
RPRX
Royalty Pharma plc
$35B 56.7% YTD
ONC
BeOne Medicines Ltd.
$34B 8.8% YTD
INCY
Incyte Corporation
$26B 31.6% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.